Novartis To Seek Label Expansion of Prostate Cancer Treatment After Successful Study

Key TakeawaysNovartis on Thursday said it will seek label expansion of its prostate cancer treatment, Pluvicto, following a successful Phase 3 study.The drug maker said Pluvicto helped improve survival rates when patients received it prior to certain chemotherapies.Novartis explained that it planned to seek approval to expand Pluvicto's use in the second half of 2024.Novartis shares were up more than 2% in late trading Thursday. Shares of Novartis (NVS) climbed Thursday as the pharmaceutical firm announced ...